Adding nelarabine to adult T-ALL therapy did not improve survival in UKALL14
In the phase 3 UKALL14 trial, one cycle of the T-cell drug nelarabine after induction was well tolerated but left event-free survival essentially unchanged in adults aged 25 to 65.
| Group | Value (%) |
|---|---|
| Standard of care | 58.2 |
| + Nelarabine | 62.7 |
Adding a single cycle of the T-cell leukaemia drug nelarabine to standard chemotherapy did not improve outcomes for adults with T-cell acute lymphoblastic leukaemia, according to final results from the T-cell arm of the UKALL14 trial [s1]. The drug was safe and well tolerated, but it did not move the measure the trial was built to move — a clean, if deflating, answer to a question the field had hoped would go the other way.
Nelarabine is already approved for T-cell acute lymphoblastic leukaemia (T-ALL) that has relapsed or stopped responding, where it can clear disease but carries a reputation for nerve toxicity. The appeal of UKALL14 was to test whether giving it earlier, as part of first-line treatment, might stop relapses before they start. That is a different and higher bar: a drug can shrink refractory disease yet still fail to change the long-run odds when added up front.
What the trial did
UKALL14 (NCT01085617) was a phase 3 randomised controlled trial sponsored by University College London — an academic study, not a company registration [s1][s2]. Its T-cell arm enrolled adults aged 25 to 65 and randomly assigned them 1:1, at trial entry, to standard of care or to standard of care plus nelarabine 1.5 g/m² given on days 1, 3, and 5 after a second induction course [s1]. The primary endpoint was event-free survival (EFS) — the share of patients alive and free of relapse or treatment failure. From 2011 to 2018, 143 patients were randomised: 75 to standard of care and 68 to standard of care plus nelarabine [s1].
Because this was a randomised comparison rather than a single-arm study, it can isolate what the added drug did, and the honest reading is that it did very little.
What it found
Event-free survival was 58.2% with standard of care and 62.7% with the addition of nelarabine — a gap too small and too uncertain to count [s1]. The hazard ratio was 0.86, with a 95% confidence interval from 0.52 to 1.43 and a P value of 0.57, meaning the result is entirely compatible with no benefit at all [s1]. The three-year cumulative incidence of relapse was likewise near-identical: 31% with standard of care versus 28.9% with nelarabine [s1].
Relapses, when they came, came fast and were hard to salvage. Forty of 44 relapses — 90.9% — occurred within two years of randomisation, and median survival after relapse was just 5.7 months, with no difference between the arms [s1]. On the safety side, the news was better: severe adverse events and non-relapse mortality did not differ between groups, and crucially there was no excess of grade 3-4 neurotoxicity, the side effect that had most worried clinicians about using nelarabine earlier [s1].
How to read it
This is a negative trial, and it is worth saying plainly rather than hunting the subgroups for a silver lining. The drug was added to a backbone that already works reasonably well, the numerical difference in EFS pointed the right way, and the confidence interval was wide — all of which can tempt a reader into reading hope into the numbers. But a 95% interval that runs from a 48% reduction in events to a 43% increase is not evidence of benefit; it is evidence that the trial could not distinguish nelarabine from no nelarabine [s1].
What the study does establish is reassuring on toxicity: one consolidation cycle at this dose did not bring the neurological harms that limit nelarabine in the relapsed setting [s1]. That matters for how the drug is positioned, even though it does not rescue the efficacy result. The speed and lethality of the relapses — most within two years, median post-relapse survival under six months — also underline why adult T-ALL remains one of the harder leukaemias to treat, and why a modestly active drug added to induction was never going to be enough on its own [s1].
For context, related coverage has examined a trial testing whether the antibody blinatumomab can replace chemotherapy in childhood acute lymphoblastic leukaemia and the FDA approval of a new bispecific antibody in follicular lymphoma.
What to watch
The useful next questions are about sequencing and selection: whether nelarabine earns its place in specific high-risk subgroups, whether measurable-residual-disease testing can identify the patients most likely to relapse, and whether newer immunotherapies change the calculus for adult T-ALL altogether [s1]. For now, UKALL14 says that bolting one cycle of nelarabine onto standard induction does not improve survival — a result that, negative as it is, saves future patients from a treatment that would not have helped.
This article describes research and is not medical advice. Decisions about leukaemia treatment belong with treating haematologists.
Sources
- One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T-cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized-controlled trial — HemaSphere , October 1, 2026
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (UKALL14) — ClinicalTrials.gov
Replacing two chemo cycles with blinatumomab raised survival in childhood leukaemia
In 709 children with high-risk B-cell ALL, swapping two chemotherapy cycles for the T-cell-engaging antibody lifted four-year event-free survival to 83% from 70% and sharply cut serious infections.
A drug pairing let many breast-cancer patients skip the harshest chemo
I-SPY2.2 tested trastuzumab-deruxtecan plus rilvegostomig before surgery in high-risk HER2-negative breast cancer. In immune-positive tumours 54% had a complete response, and most of them avoided anthracyclines.
New ALK inhibitor more than doubled progression-free time versus crizotinib in NSCLC
In a Chinese phase 3 trial of 275 patients with ALK-positive advanced lung cancer, dirozalkib delayed progression to a median of 29.5 months against 12.9 on crizotinib. No survival result yet.
A shorter trifluridine–tipiracil schedule matched the standard in bowel cancer
In PRABITAS, 970 patients with refractory metastatic colorectal cancer were randomised to a 14-day or 28-day schedule. Median survival was 11.3 versus 10.3 months, and severe neutropenia fell from 39% to 13%.